Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), has announced a strategic partnership with Belgium-based ExeVir Bio. The collaboration aims to explore the infectious disease sector, with no financial details or other specifics disclosed at this time.
ExeVir Bio’s Nanoantibody-Based Therapy Platform
ExeVir Bio is a clinical biotechnology company specializing in nanoantibody-based therapies for infectious diseases. The company utilizes its VHH technology platform, which is based on camel-derived antibodies, to develop multi-specific antibodies designed to prevent and treat infectious diseases. This innovative approach has the potential to revolutionize the way infectious diseases are managed.
Core Asset XVR012 and Its Potential Impact
ExeVir Bio’s core asset, XVR012, is a COVID-19-neutralizing antibody that showcases the company’s capabilities in addressing global health challenges. The partnership with Nona Biosciences is expected to leverage ExeVir’s expertise in nanoantibody technology to develop new therapies and treatments for a range of infectious diseases.-Fineline Info & Tech
